Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
Biogen will present new long-term EMPAVELI (pegcetacoplan) Phase 3 data at ASN Kidney Week (Oct 22-25, 2026), including 76-week results showing sustained proteinuria reduction and continued eGFR stabilization in C3G and primary IC-MPGN with a consistent safety profile. The data reinforce EMPAVELI's recently expanded U.S. FDA label as the first and only therapy approved to reduce both proteinuria and loss of kidney function in these diseases.
Key figures
- Drug Name
- EMPAVELI (pegcetacoplan)
- Phase Of Trial
- Phase 3
- Weeks of data
- 76
- Transcend data expected
- H1 2027
- Felzartamab phase3 trials
- ["TRANSCEND (AMR)","PREVAIL (IgA nephropathy)","PROMINENT (primary membranous nephropathy)"]
- Kidney diseases in research
- 7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.